Abstract: SA-PO497
Etelcalcetide Use Affects Changes in Agatston Coronary Artery Calcium (CAC) Score in Maintenance Dialysis Patients
Session Information
- Hypertension and CVD: Clinical - II
November 04, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Hypertension and CVD
- 1602 Hypertension and CVD: Clinical
Authors
- Doi, Toshiki, Ichiyokai Harada Hospital, Hiroshima, Japan
- Morii, Kenichi, Ichiyokai Harada Hospital, Hiroshima, Japan
- Mizuiri, Sonoo, Ichiyokai Harada Hospital, Hiroshima, Japan
- Nishizawa, Yoshiko, Ichiyokai Harada Hospital, Hiroshima, Japan
- Masaki, Takao, Hiroshima Daigaku Byoin, Hiroshima, Hiroshima, Japan
Background
Dialysis patients are known to be at high cardiovascular risk, and the Agatston CAC score, a measure of coronary artery calcification, has been associated with cardiovascular events. Recently, calcimimetics such as etelcalcetide have been used to manage secondary hyperparathyroidism, but their effect on vascular calcification is unknown. Therefore, the present study investigated whether etelcalcetide use affects changes in Agatston CAC scores in maintenance hemodialysis patients.
Methods
This historical cohort study included 192 patients undergoing maintenance hemodialysis who had Agatston CAC score of 100 or higher and were not using calcimimetics other than etelcalcetide. Propensity score matching was performed by age, gender, diabetes mellitus, Ca, iP, and intact PTH. In addition, we examined whether there was a difference in etelcalcetide use and the rate of change in Agatston CAC score after one year.
Results
In the two groups of patients matched for background factors by propensity scores (18 patients each), the Agatston CAC score change was significantly lower in the etelcalcetide use group (p = 0.0284).
Conclusion
Etelcalcetide use in maintenance dialysis patients may reduce coronary calcification.